Treatment proven to demonstrate significant survival improvement in patients with mCRC whose disease has progressed despite treatment with oxaliplatin-based regimen2 Sanofi and Regeneron Pharmaceuticals, Inc. announced today that they have launched ZALTRAP (aflibercept) which is licensed for use...